Loading
A phase 1/2 trial of BNT324 and Enzalutamide in advanced solid tumours, run by DualityBio Inc., now recruiting.
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05914116 by DualityBio Inc., with 862 participants planned, started 2023-08-17 and due to reach its primary completion in 2027-12. Interventions recorded: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide and Abiraterone.
Shares BNT324, Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BNT324, Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.